CHAPTER 3 64 20. Vrede SW, van Weelden WJ, Visser NCM, Bulten J, van der Putten LJM, van de Vijver K, et al. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer. Gynecol Oncol. 2021;161(3):787-94. 21. Visser NCM, van der Wurff AAM, IntHout J, Reijnen C, Dabir PD, Soltani GG, et al. Improving preoperative diagnosis in endometrial cancer using systematic morphological assessment and a small immunohistochemical panel. Hum Pathol. 2021;117:68-78. 22. Hamilton CA, Pothuri B, Arend RC, Backes FJ, Gehrig PA, Soliman PT, et al. Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations. Gynecol Oncol. 2021;160(3):817-26. 23. Sheikh A, Netuveli G, Kai J, Panesar SS. Comparison of reporting of ethnicity in US and European randomised controlled trials. Bmj. 2004;329(7457):87-8. 24. Lu KH, Broaddus RR. Endometrial Cancer. N Engl J Med. 2020;383(21):2053-64.
RkJQdWJsaXNoZXIy MTk4NDMw